BML Investment lists 13.95M shares (9.9%) in Aclaris (NASDAQ: ACRS)
Rhea-AI Filing Summary
BML Investment Partners, L.P. filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership of 13,950,000 shares of Aclaris Therapeutics common stock, representing 9.9% of the class based on 139,663,680 shares outstanding as disclosed on a DEF 14A dated 4/23/2026. The filing states shared voting and dispositive power over these shares and includes a signature block explaining indirect ownership through BML Capital Management, LLC and Braden M. Leonard, with a disclaimer that the reporting persons do not constitute a statutory group under Rule 13d-5(b)(1).
Positive
- None.
Negative
- None.
Key Figures
Beneficially owned shares: 13,950,000 shares
Percent of class: 9.9%
Shares outstanding (source): 139,663,680 shares
+2 more
5 metrics
Beneficially owned shares
13,950,000 shares
Amount beneficially owned reported on Schedule 13G/A
Percent of class
9.9%
Percent of common stock based on disclosed outstanding shares
Shares outstanding (source)
139,663,680 shares
Shares outstanding as disclosed on DEF 14A filed 4/23/2026
Shared voting power
13,950,000 shares
Shared power to vote or direct the vote reported in Item 4
Sole voting/dispositive power
0 shares
No sole voting or sole dispositive power reported in Item 4
Key Terms
Schedule 13G/A, shared dispositive power, beneficial ownership
3 terms
Schedule 13G/A regulatory
"filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficial ownership financial
"Amount beneficially owned: 13950000 (b) Percent of class: 9.9 %"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stake does BML Investment Partners report in Aclaris Therapeutics (ACRS)?
BML Investment Partners reports beneficial ownership of 13,950,000 shares, equal to 9.9% of the outstanding common stock. The percentage is based on 139,663,680 shares outstanding as disclosed on a DEF 14A filed 4/23/2026.
Who is the reporting person and how is indirect ownership described?
The reporting person is BML Investment Partners, L.P.. The signature explains that BML Capital Management, LLC is the sole general partner and Braden M. Leonard is the managing member, making him an indirect owner of the shares.
Is BML Investment Partners claiming to be part of a statutory group for ACRS holdings?
No. The filing includes a disclosure that, despite shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group under Rule 13d-5(b)(1), as stated in the signature commentary.
What document is the ownership percentage tied to in the filing?
The 9.9% ownership calculation is tied to 139,663,680 shares outstanding, which the filing cites as disclosed by the issuer on a DEF 14A filed on 4/23/2026. This provides the time anchor for the percentage.